Jefferies reiterated its Buy rating on Vanda Pharmaceuticals VNDA. At the same time, the rating agency reduced its price target on the company's stock from $10 to $8.50. On Friday, VNDA lost 0.44% of its value to finish the day at $6.75.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
